Table 1 Clinical characteristics and treatment of patients, Tumor volume, marginal dose and prescribed isodose were statistically significant different between the VS and M group
Patient characteristics | |
|---|---|
Patients | 245 |
Gender (m:f) | 81:164 |
Age (years) | |
Median (range) | 71 (65–86) |
Mean (SD) | 71.8 ± 5.2 |
Vestibular schwannoma | 116 (47.3%) |
Meningioma | 129 (52.7%) |
Pre-therapeutic comorbidities | |
|---|---|
Patients with any comorbidities | 171 (69.8%) |
Multimorbid patients (≥ 2 diseases) | 30 (12.2%) |
Comorbidity of vascular disease | 97 (39.66%) |
Comorbidity of metabolic disease | 54 (22%) |
Comorbidity of malignant tumor | 25 (10.2%) |
Vestibular schwannoma (VS) | Meningioma (M) | p value | |
|---|---|---|---|
Tumor characteristics | |||
Treatment indication | |||
Tumor growth | 53 (45.7%) | 80 (62%) | |
Residual tumor after resection | 1 (0.9%) | 5(3.9%) | |
Symptoms | 62 (53.4%) | 43 (33.3%) | |
Inquiry of patient | – | 1 (0.8%) | |
Pretreated tumors | 20 (17.2%) | 42 (32.6%) | |
Pretreatment with surgery | 20 (100%) | 37 (88%) | |
Pretreatment with surgery + radiotherapy | – | 5 (12%) | |
Radiological and clinical follow up available | 94 (81%) | 114 (89%) | |
Radiological follow up (months), mean (SD) | 45.5 ± 41.2 | 40 ± 36.6 | 0.35 |
Median (range) | 30 (2–173) | 26 (4–181) | |
≥ 60 months to last radiological FU | 25 (26.6%) | 28 (24%) | |
Tumor volume (cm3) | < 0.0001 | ||
Mean (SD) | 2.7 ± 3.2 | 5.8 ± 4.6 | |
Median (range) | 1.6 (0.1–23.7) | 4.8 (0.2–28) | |
Radiosurgery parameters | |||
LINAC (1991–2012), number of patients | 99 (85.3%) | 73 (56.6%) | |
CK (2013–2015), number of patients | 17 (14.7%) | 56 (43.4%) | |
Marginal dose (Gy), mean (SD) | 12.3 ± 0.7 | 12.5 ± 1.2 | < 0.002 |
Median (range) | 12 (11–15) | 12 (7–20) | |
Dose prescription isodose (%), mean (SD) | 68.3 ± 12.7 | 74 ± 7.6 | < 0.0001 |
Median (range) | 70 (33.4–85.1) | 78 (36–80) | |